ARCHIVES

In Brief: David Feigal To Head FDA’s Antiviral Division; ODAC To Discuss Melphalan, Amifostine NDAs

This article is from The Cancer Letter archive.

Vol. 18 No. 03 | January 17, 1992

Download PDF Visit The Full Archive

Related Articles

Vectibix Non-Inferior to Erbitux In Wild-Type Metastatic Disease

October 25, 2013

“Confidential and Proprietary” Document Proposes Plan for National Network

February 7, 2014

NCAB TO Reconsider Decision Not To Fund Diet Fit Trial

October 20, 1989

NCI’s Independence To Be Challenged By Edwards When Cancer Act Comes Up For Renewal Next Year

December 21, 1973

Analyzing Tumor Tissue In Clinical Trials Can Improve Outcomes, RTOG Trial Finds

May 27, 2011

NCI Awards $6.7 Million For Breast Cancer Research.

September 8, 2000